Skip to Main Content

5,523

Views

12

CrossRef citations to date

0

Altmetric

Novel Vaccines – Research Paper

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

Kevin L. Russella Merck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
View further author information

,

Richard E. Ruppb Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA

https://orcid.org/0000-0002-9659-1217 View further author information

,

Javier O. Morales-Ramirezc Clinical Research Puerto Rico, San Juan, Puerto RicoView further author information

,

Clemente Diaz-Perezd University of Puerto Rico School of Medicine, San Juan, Puerto RicoView further author information

,

Charles P. Andrewse Diagnostics Research Group, San Antonio, TX, USAView further author information

,

Andrew W. Leea Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Tyler S. Finna Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Kara S. Coxa Merck & Co., Inc., Kenilworth, NJ, USA

https://orcid.org/0000-0002-5798-2944 View further author information

,

Amy Falk Russella Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Margaret M. Schallera Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Jason C. Martina Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Donna M. Hyatta Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Sabrina Gozlan-Kelnera Merck & Co., Inc., Kenilworth, NJ, USAView further author information

,

Androniki Bilia Merck & Co., Inc., Kenilworth, NJ, USAView further author information

&

Beth-Ann G. Collera Merck & Co., Inc., Kenilworth, NJ, USAView further author information